Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there - 2Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- 3Instructions to Boost Your True capacity with a Brain research Degree
- 4Investigate Something else for Less: Financial plan Travel Objections
- 56 Eyewear Brands Worth Purchasing
- 5 Great Youngster Care Administrations To Watch in 2024
- Survey: Canteen Cups With Great Warm Protection Impact
- Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
- The Significance of a Land Lawyer for Your Business
- Ancient Pompeii construction site reveals the process for creating Roman concrete
- Russia accidentally destroys its only way of sending astronauts to space
- Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- The Best 20 Photography Instagram Records to Follow
- AI is providing emotional support for employees – but is it a valuable tool or privacy threat?
